CAJ | 학술논문

目的：研究吉非替尼口服并胸腔内注入力尔凡治疗晚期胸膜转移肺腺癌的临床效果。方法选取晚期胸膜转移肺腺癌患者88例，根据治疗方法将88例患者均分为观察组和对照组（各44例）。对照组采取胸腔积液引流后口服吉非替尼治疗，但是不给予胸腔内注药。观察组采取胸腔引流胸腔积液后注入400 mg力尔凡。两组患者均每个月进行胸部B超和CT检查。对比两组患者临床疗效及不良反应发生情况。结果治疗后观察组胸腔积液控制率、肿瘤病灶控制率、3个月疾病控制率、临床收益率显著高于对照组，具有统计学意义（P＜0．05）。治疗后观察组胸痛、发热、轻度皮疹、中度皮疹、轻度腹泻等不良反应的发生率显著低于对照组，差异具有统计学意义（ P＜0．05）。结论使用吉非替尼口服并胸腔内注入力尔凡治疗晚期胸膜转移肺腺癌有较好的临床疗效，不良反应的发生率也较低，可以在临床上进一步推广和使用。
목적：연구길비체니구복병흉강내주입력이범치료만기흉막전이폐선암적림상효과。방법선취만기흉막전이폐선암환자88례，근거치료방법장88례환자균분위관찰조화대조조（각44례）。대조조채취흉강적액인류후구복길비체니치료，단시불급여흉강내주약。관찰조채취흉강인류흉강적액후주입400 mg력이범。량조환자균매개월진행흉부B초화CT검사。대비량조환자림상료효급불량반응발생정황。결과치료후관찰조흉강적액공제솔、종류병조공제솔、3개월질병공제솔、림상수익솔현저고우대조조，구유통계학의의（P＜0．05）。치료후관찰조흉통、발열、경도피진、중도피진、경도복사등불량반응적발생솔현저저우대조조，차이구유통계학의의（ P＜0．05）。결론사용길비체니구복병흉강내주입력이범치료만기흉막전이폐선암유교호적림상료효，불량반응적발생솔야교저，가이재림상상진일보추엄화사용。
Objective To study the clinical efficacy of oral gefitinib and intrapleural injection of lifein for advanced pleural metastasis of lung adenocarcinoma.Methods 88 cases of patients with advanced pleural metastasis of lung adenocarcino-ma,according to the treatment methods,were divided into the observation group and the control group,each with 44 cases.The control group received oral gefitinib after pleural effusion drainage,and no intrathoracic injection of medicine.The observation group received the chest drainage of pleural effusion and injection of 400 mg lifein.Both groups received chest ultrasound and CT examination every month.Clinical efficacy and adverse reactions of the 2 groups were compared.Results Pleural effusion control rate,tumor lesion control rate,3-month disease control rate,and clinical yields in the observation group after treatment were signif-icantly higher than those of the control group,there had statistically significant difference (P<0.05).The incidence of adverse reactions such as chest pain,fever,mild rash,moderate rash,and mild diarrhea in the observation group after treatment were sig-nificantly lower than those of the control group (P<0.05).Conclusion Oral gefitinib and intrapleural injection of lifein for ad-vanced pleural metastasis of lung adenocarcinoma is effective with lower incidence of adverse reactions,and it is worthy of further clinical promotion and application.